Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Discovery's breathing disorder drug Surfaxin

Will be the first non animal-based treatment available for respiratory distress syndrome

The US Food and Drug Administration (FDA) has approved Discovery Laboratories' Surfaxin (lucinactant) to prevent a breathing disorder in infants.

The US regulator licensed it for the prevention of respiratory distress syndrome (RDS) – a condition that arises in premature infants who cannot make enough surfactant, a liquid that coats the inside of the lungs.

The lack of this coating, which helps the lungs to open, can lead to breathing difficulties and lung collapse.

Surfaxin, which Discovery expects to launch in the US in late 2012, is the first synthetically-created drug for the condition to be licensed in the US.

The existing four alternatives, including Abbott's Suvanta (beractant), Chiesi's Curosurf (poractant alpha) and Ony's Infasurf (calfactant) are all animal-based products.

Another product, Exosurf (colfosceril palmitate) developed by GlaxoSmithKline, is no longer marketed.

According to Discovery Labs, about 90,000 premature babies are treated for RDS each year with these animal-based surfactants.

“The approval of Surfaxin is an important medical advancement for the neonatology community and parents of preterm infants who will soon have an effective alternative to animal-derived surfactants to prevent the development of RDS,” said W Thomas Amic, chair and CEO of Discovery Labs.

The FDA's decision is based on a phase III clinical trial involving 1,294 premature infants. Within 30 minutes of birth, infants received either Surfaxin, Exosurf or Survanta, with Exosurf serving as the primary comparison in the study. Sufaxin demonstrating significant improvement in both RDS 24 hours after birth and RDS-related mortality over two weeks compared to Exosurf.

Side effects mainly related to the mechanism of use for the drug, with its administration involving an inserting an endotracheal tube into the infant.

The FDA had originally delayed its decision due to concerns over the drug's shelf life and manufacturing issues.

8th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...

Infographics